1.List the top 20 questions your team needs to answer to advance the venture forward. Categorize the questions if necessary.
- How can the accuracy of our product be improved?
- Will the current infrastructure of health services in Sierra Leone be able to easily integrate our product?
- How can we reduce the cost of per strip test?
- Which design of the test itself is the most effective for accuracy as well as ease of use?
- How can we ensure/convince people to use our product as a regular part of post-childbirth care?
- What specific data are we looking to gather in Sierra Leone?
- How can we continue to develop current as well as establish new partnerships with those in Sierra Leone?
- How should we continue searching for funding for our venture? What proposals do we need to be writing and when are those applications due?
- What kind of system will it take to mass produce and distribute our product?
- What is the most important information to gather while in Sierra Leone to further the venture?
- Is our product currently too complex for health care workers?
- What is the most effective way to train health care workers to use the product in a consistent and replicable way?
- What is the best use of our current data when applying for grants/funding?
- What information is most useful in trying to convince others of this product’s effectiveness/usefulness?
- How can information on Sickle Cell Disease best be spread throughout different populations?
- What does post-diagnosis treatment and care look like? Does it need improvement and how can we help with that?
- Who will be in charge of producing the device in the long term?
- How can we prevent cross contamination on our product?
- What sort of interviews should we be conducting when in Sierra Leone? What questions will we be asking locals?
- How can our plan be improved to help the most people possible?
2.Develop and Visualize the Theory of Change (Logic Model) for your venture.
Inputs
- Lab work, reagents, materials, time and labor to produce prototypes
- collaboration with global partners and other sickle cell organizations
Outputs (Activities)
- A more accurate and inexpensive product
- System for treatment following diagnosis
- System for mass production and use of the product
- Train and educate medical professionals on a repeatable method to use the device effectively – measured by the number of clinics that have implemented our device
- Number of children who are diagnosed correctly and are able to receive treatment
Outputs (Participation)
- Trained medical professionals who know how to use the device and give effective plan of care based on results
- Guidance from Sickle Cell Advocacy groups and World Hope International on how to maximize use and benefits
Outcomes (short)
- Raise awareness of Sickle Cell Disease
- Increased rate of SCD screening
- Increased access to diagnostic screening for Sickle Cell Anemia
- Increased birth planning, especially among those carrying the sickle cell trait or those who have the disease
- Medical staff will be able to educate mothers or legal guardians on how to receive treatment for SCD
Outcomes (long)
- Reduce mortality rate of children across Sierra Leone due to Sickle cell anemia
- Widespread access to a diagnostic device for sickle cell
- Community members fully educated on their options for treatment after diagnosis and how to proceed with carrier status
- Increased life expectancy of children diagnosed with Sickle Cell in Sierra Leone
Assumptions
- Hospitals will be cooperative in implementing our device
- Many patients/parents of children will consent to be screened for SCD
External Factors
- Economy fluctuations
- Political instability
- Government regulations (pandemic)
3.Develop a M&E plan for your venture.
Clearly list all assumptions.
Identify short-term and long-term success metrics.
(Optional) identify specific methods to measure the metrics.
INDICATOR | DEFINITION
How is it calculated? |
BASELINE
What is the current value? |
TARGET
What is the target value? |
DATA SOURCE
How will it be measured? |
FREQUENCY
How often will it be measured? |
RESPONSIBLE
Who will measure it? |
REPORTING
Where will it be reported? |
|
Goal | Reduce mortality rate of children across sub-Saharan Africa due to Sickle cell anemia | Number of children under the age of five who have died due to sickle cell anemia in the past year divided by the number of live births, times 100 | Currently, 50 to 90% of SCD-affected children are dying before the age of five in Sub-Saharan Africa (Grosse, S. D., Odame, I., Atrash, H. K., Amendah, D. D., Piel, F. B., & Williams, T. N. (2011). Sickle cell disease in Africa: a neglected cause of early childhood mortality. American journal of preventive medicine, 41(6 Suppl 4), S398-S405. doi: 10.1016/j.amepre.2011.013 | 200 test strips to be administered for diagnostic testing | Hospital records of deaths of children in sub-saharan Africa who were diagnosed of SCD and died under the age of five | Annually | CDC’s National Vital Statistics System (NVSS) captures all deaths from all causes across every state in the nation | Annual hospital records |
Outcomes | Rate of children being tested for Sickle cell anemia when born in sub-Saharan Africa | Number of children being tested at birth divided by the number of live births, times 100 | Percentage of early diagnosis of children with SCD using our test strip device | Distribution of numbers of individuals with sickle cell disease, with the trait, and with normal hemoglobin amongst 200 test stips administered. | Annually | Our team in collaboration with global partners (World Hope International and other Sickle Cell Disease Organizations) | Organization of records of those diagnosed with SCD and SCD trait to plan for treatment based on the use of our device | |
Outputs | Raise awareness on the importance of diagnosing sickle cell anemia in order to reduce child mortality rates. |
Number of children diagnosed with sickle cell anemia divided by the number of live births, times 100
Number of children diagnosed with sickle cell anemia trait divided by the number of live births, times 100 |
Percentage of children with SCD who need treatment and care to prevent mortality |
Numbers of individuals with SCD relative to total population in need of treatment plan to prevent mortality |
Annually |
Trained medical professionals and guidance from groups Community members more educated on importance of testing themselves and their children for SCD and how to receive treatment Increased birth planning |
Raised Awareness of SCD prevalence in Sierra Leone communities
Continuous testing of our device based on reported records of diagnoses and success and reliability of our device |
Collaborated on by: Kathleen Gifford, Anjali Shah, and Lauryn Jones